Ionis expands Otsuka license for donidalorsen in Asia-Pacific; $20M upfront

IONIS PHARMACEUTICALS INC

Otsuka gains exclusive rights to commercialize donidalorsen (HAE) in Asia-Pacific; Ionis retains US rights.
Ionis receives $20M upfront, plus milestone payments and tiered royalties similar to the Europe deal.
Ionis plans to file U.S. NDA for donidalorsen in 2024 and launch independently if approved.
Otsuka will handle Asia-Pacific and Europe regulatory filings and commercialization; Ionis leads global development.
Positive Phase 3 OASIS-HAE and OASISplus results were recently published in NEJM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.